A Randomized prospective study comparing efficacy of 0.5% Hyperbaric Levobupivacaine with 0.5% Hyperbaric Bupivacaine for subarachnoid block in Orthopedic lower limb surgeries

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/01/048768

Enrollment

120

Registered

2023-01-05

Start date

Unknown

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: W010- Fall on same level from slipping,tripping and stumbling without subsequent striking against object Health Condition 2: W183- Other and unspecified fall on samelevel Health Condition 3: S729- Unspecified fracture of femur

Interventions

Intervention1: LEVOBUPIVACAINE HEAVY: 3ml of 0.5% LEVOBUPIVACAINE HEAVY IN SUBARACHNOID BLOCK Control Intervention1: 0.5% BUPIVACAINE HEAVY: 3ml OF 0.5% BUPIVACAINE IN SUBARACHNOID BLOCK

Eligibility

Inclusion criteria

Inclusion criteria: Adult (Age >= 18 - 60 Years) undergoing orthopedic lower limb surgeries under Subarachnoid block 2 . ASA grade I and II 3.Anticipated Duration of surgery 120 minutes

Exclusion criteria

Exclusion criteria: 1. Patient refusal to participate in study 2. Contraindication to subarachnoid block 3. Patients with height 180 cm 4. Patients with BMI >= 30 5. Patient with history of allergy to local anaesthetics

Design outcomes

Primary

Measure	Time frame
To compare the onset and duration of sensory block with 0.5% Hyperbaric Levobupivacaine and 0.5% Hyperbaric Bupivacaine after subarachnoid block in adult patients undergoing Orthopedic lower limb surgeries . Timepoint: SEPTEMBER 2022 TO JUNE2024	—

Secondary

Measure	Time frame
To determine the following parameters in patients receiving 0.5% Hyperbaric Levobupivacaine and 0.5% Hyperbaric Bupivacaine: 1. Onset and duration of motor block 2. Hemodynamic stability 3. Total dose of vasopressor required 4. Incidences of intraoperative complications: Hypotension, Bradycardia, Nausea and Vomiting Timepoint: SEPTEMBER2022 TO JUNE 2024	—

Countries

India

Contacts

Public ContactDr SHARAD KUMAR

TATA MAIN HOSPITAL,JAMSHEDPUR

drskumar@tatasteel.com7763807750

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026